162 related articles for article (PubMed ID: 25906254)
1. mLST8 Promotes mTOR-Mediated Tumor Progression.
Kakumoto K; Ikeda J; Okada M; Morii E; Oneyama C
PLoS One; 2015; 10(4):e0119015. PubMed ID: 25906254
[TBL] [Abstract][Full Text] [Related]
2. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the Scaffolding Function of mLST8 Selectively Inhibits mTORC2 Assembly and Function and Suppresses mTORC2-Dependent Tumor Growth
Hwang Y; Kim LC; Song W; Edwards DN; Cook RS; Chen J
Cancer Res; 2019 Jul; 79(13):3178-3184. PubMed ID: 31085701
[TBL] [Abstract][Full Text] [Related]
4. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
5. Growth-factor dependent expression of the translationally controlled tumour protein TCTP is regulated through the PI3-K/Akt/mTORC1 signalling pathway.
Bommer UA; Iadevaia V; Chen J; Knoch B; Engel M; Proud CG
Cell Signal; 2015 Aug; 27(8):1557-68. PubMed ID: 25936523
[TBL] [Abstract][Full Text] [Related]
6. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
7. Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines.
Murai A; Asa SA; Kodama A; Hirata A; Yanai T; Sakai H
BMC Vet Res; 2012 Jul; 8():128. PubMed ID: 22839755
[TBL] [Abstract][Full Text] [Related]
8. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.
Guertin DA; Stevens DM; Thoreen CC; Burds AA; Kalaany NY; Moffat J; Brown M; Fitzgerald KJ; Sabatini DM
Dev Cell; 2006 Dec; 11(6):859-71. PubMed ID: 17141160
[TBL] [Abstract][Full Text] [Related]
9. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling.
Wang B; Jie Z; Joo D; Ordureau A; Liu P; Gan W; Guo J; Zhang J; North BJ; Dai X; Cheng X; Bian X; Zhang L; Harper JW; Sun SC; Wei W
Nature; 2017 May; 545(7654):365-369. PubMed ID: 28489822
[TBL] [Abstract][Full Text] [Related]
10. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
11. STAT3-mediated MLST8 gene expression regulates cap-dependent translation in cancer cells.
Lee H; Chin H; Kim H; Jung H; Lee D
Mol Oncol; 2020 Aug; 14(8):1850-1867. PubMed ID: 32495998
[TBL] [Abstract][Full Text] [Related]
12. MiR-424/503-mediated Rictor upregulation promotes tumor progression.
Oneyama C; Kito Y; Asai R; Ikeda J; Yoshida T; Okuzaki D; Kokuda R; Kakumoto K; Takayama K; Inoue S; Morii E; Okada M
PLoS One; 2013; 8(11):e80300. PubMed ID: 24244675
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.
Luo Y; Liu L; Wu Y; Singh K; Su B; Zhang N; Liu X; Shen Y; Huang S
Oncotarget; 2015 Feb; 6(6):4286-98. PubMed ID: 25738366
[TBL] [Abstract][Full Text] [Related]
14. Aschantin targeting on the kinase domain of mammalian target of rapamycin suppresses epidermal growth factor-induced neoplastic cell transformation.
Lee CJ; Jang JH; Lee JY; Lee MH; Li Y; Ryu HW; Choi KI; Dong Z; Lee HS; Oh SR; Surh YJ; Cho YY
Carcinogenesis; 2015 Oct; 36(10):1223-34. PubMed ID: 26243309
[TBL] [Abstract][Full Text] [Related]
15. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
[TBL] [Abstract][Full Text] [Related]
17. Dynamic modelling of the PI3K/MTOR signalling network uncovers biphasic dependence of mTORC1 activity on the mTORC2 subunit SIN1.
Ghomlaghi M; Yang G; Shin SY; James DE; Nguyen LK
PLoS Comput Biol; 2021 Sep; 17(9):e1008513. PubMed ID: 34529665
[TBL] [Abstract][Full Text] [Related]
18. MiR-99a Inhibits Cell Proliferation and Tumorigenesis through Targeting mTOR in Human Anaplastic Thyroid Cancer.
Huang HG; Luo X; Wu S; Jian B
Asian Pac J Cancer Prev; 2015; 16(12):4937-44. PubMed ID: 26163618
[TBL] [Abstract][Full Text] [Related]
19. Disruption of the Keap1-mTORC2 axis by cancer-derived Keap1/mLST8 mutations leads to oncogenic mTORC2-AKT activation.
Chen Y; Jiao D; He H; Sun H; Liu Y; Shi Q; Zhang P; Li Y; Mo R; Gao K; Wang C
Redox Biol; 2023 Nov; 67():102872. PubMed ID: 37688978
[TBL] [Abstract][Full Text] [Related]
20. PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.
Liu P; Gan W; Chin YR; Ogura K; Guo J; Zhang J; Wang B; Blenis J; Cantley LC; Toker A; Su B; Wei W
Cancer Discov; 2015 Nov; 5(11):1194-209. PubMed ID: 26293922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
